Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients(MM) | withdrawn | Phase 4 | 0 | Al-Rasheed University CollegeOTHER | 1 |
| Apr 28, 2023 |
| clinicaltrials |
| NCT05316831 | Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia | completed | Phase 4 | 77 | Region Örebro CountyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05786989 | Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 32 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT02286830 | Prolonged Protection From Bone Disease in Multiple Myeloma(Magnolia) | completed | Phase 4 | 158 | Thomas LundOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | unknown | Phase 4 | 290 | Ruijin HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia(LABMI) | terminated | Phase 4 | 119 | University Hospital, AngersOTHER_GOV | 1 | Oct 3, 2022 | clinicaltrials |
| NCT03619252 | Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents | completed | Phase 4 | 36 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT00199082 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | completed | Phase 4 | 650 | Nicola GoekbugetOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT04989140 | Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide | unknown | Phase 4 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00622505 | Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants(Z-MARK) | completed | Phase 4 | 121 | Novartis PharmaceuticalsINDUSTRY | 1 | May 26, 2021 | clinicaltrials |
| NCT04842318 | Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | unknown | Phase 4 | 789 | Ruijin HospitalOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04612582 | Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | unknown | Phase 4 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01087008 | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse(AZABACHE) | completed | Phase 4 | 103 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01731886 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | completed | Phase 4 | 60 | Columbia UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma(Velcadito) | terminated | Phase 4 | 24 | Basque Health ServiceOTHER_GOV | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02958969 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | completed | Phase 4 | 50 | Gregory PiazzaOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03908138 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04152577 | R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL | unknown | Phase 4 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04083066 | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03376958 | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | completed | Phase 4 | 32 | Zhengzhou UniversityOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT03579082 | A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 60 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02559154 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | unknown | Phase 4 | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT03513601 | Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma(MM) | withdrawn | Phase 4 | 0 | DFINE Inc.INDUSTRY | 0 | Jan 20, 2017 | clinicaltrials |
| NCT02992834 | Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma | unknown | Phase 4 | 10 | jiangjingtingOTHER | 1 | Dec 14, 2016 | clinicaltrials |
| NCT02268890 | A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | completed | Phase 4 | 18 | Johnson & Johnson Taiwan LtdINDUSTRY | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01949818 | Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 120 | Mingzhi ZhangOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT01255644 | Antiviral Treatment of Chronic Lymphocytic Leukemia(VGCV-CLL) | completed | Phase 4 | 20 | Medical University of ViennaOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01960192 | Treatment of Primary CNS Lymphoma(FVD) | unknown | Phase 4 | 50 | Mingzhi ZhangOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01056510 | A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) | completed | Phase 4 | 357 | Hoffmann-La RocheINDUSTRY | 8 | Jun 25, 2015 | clinicaltrials |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. | withdrawn | Phase 4 | 0 | NovartisINDUSTRY | 0 | Apr 14, 2015 | clinicaltrials |
| NCT00352703 | PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation | completed | Phase 4 | 145 | Swedish Orphan BiovitrumINDUSTRY | 0 | Nov 3, 2014 | clinicaltrials |
| NCT00919321 | The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL(KLL2) | completed | Phase 4 | 32 | Tampere University HospitalOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01990807 | Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia | unknown | Phase 4 | 20 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01868828 | A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | unknown | Phase 4 | 50 | Peking University People's HospitalOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00104104 | A Multiple Myeloma Trial in Patients With Bone Metastases | completed | Phase 4 | 179 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT01249690 | Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma | unknown | Phase 4 | 100 | Second Military Medical UniversityOTHER | 1 | Nov 30, 2010 | clinicaltrials |
| NCT00466258 | LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)(LINFOTARGAM) | completed | Phase 4 | 50 | PETHEMA FoundationOTHER | 1 | Nov 25, 2009 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jun 2, 2023source: clinicaltrials